大剂量二联方案在根除幽门螺杆菌中的应用进展
Application Progress of High-Dose Dual Therapy in the Eradication of Helicobacter Pylor
DOI: 10.12677/jcpm.2024.34194, PDF,   
作者: 萨础拉：内蒙古民族大学临床医学院，内蒙古 通辽；安桂凤*：内蒙古民族大学附属医院消化内科，内蒙古 通辽
关键词: 幽门螺杆菌；二联疗法；伏诺拉生；Helicobacter Pylori； Dual Therapy； Vonoprazan
摘要: 幽门螺杆菌是寄生于胃和十二指肠的一种细菌。长期HP感染导致慢性萎缩性胃炎、消化性溃疡、胃黏膜相关组织淋巴瘤、胃癌等消化系统疾病，还与胃肠以外特发性血小板性紫癜、不明原因缺铁性贫血、维生素B12吸收不良、阿尔茨海默病、神经退行性疾病等疾病相关。在抗生素耐药率日益增高的情况下，三联疗法或四联疗法根除率逐渐下降，随之继发耐药率升高。近些年研究表明大剂量二联疗法在HP根除率中与铋剂四联疗法相当，本文就对大剂量二联疗法做一探讨。
Abstract: Helicobacter pylori is a bacterium inhabiting the stomach and duodenum. Long-term HP infection leads to chronic atrophic gastritis, peptic ulcer, gastric mucosa associated tissue lymphoma, gastric cancer and other digestive system diseases, and is also associated with extra-gastrointestinal idiopathic thrombocytopenic purpura, unexplained iron deficiency anemia, vitamin B12 malabsorption, Alzheimer’s disease, neurodegenerative diseases and other diseases. In the case of increasing antibiotic resistance rate, the eradication rate of triple therapy or quadruple therapy gradually decreased, and the secondary resistance rate increased. Recent studies have shown that high-dose dual therapy is comparable to bismuth quadruple therapy in HP eradication rate. This article will discuss the high-dose dual therapy.
文章引用：萨础拉, 安桂凤. 大剂量二联方案在根除幽门螺杆菌中的应用进展[J]. 临床个性化医学, 2024, 3(4): 1371-1376. https://doi.org/10.12677/jcpm.2024.34194

参考文献

[1] Sugano, K., Tack, J., Kuipers, E.J., Graham, D.Y., El-Omar, E.M., Miura, S., et al. (2015) Kyoto Global Consensus Report Onhelicobacter Pylorigastritis. Gut, 64, 1353-1367. [Google Scholar] [CrossRef] [PubMed]
[2] Tshibangu-Kabamba, E. and Yamaoka, Y. (2021) Helicobacter Pylori Infection and Antibiotic Resistance—From Biology to Clinical Implications. Nature Reviews Gastroenterology & Hepatology, 18, 613-629. [Google Scholar] [CrossRef] [PubMed]
[3] Sato, C., Hirasawa, K., Tateishi, Y., Ozeki, Y., Sawada, A., Ikeda, R., et al. (2020) Clinicopathological Features of Early Gastric Cancers Arising in helicobacter Pylori Uninfected Patients. World Journal of Gastroenterology, 26, 2618-2631. [Google Scholar] [CrossRef] [PubMed]
[4] 韩莹莹, 方丹, 官佳轮, 王慕茹, 田德安, 黎培员. 阿莫西林和质子泵抑制剂二联治疗幽门螺杆菌感染的研究进展[J]. 中华消化杂志, 2022, 42(2): 137-140.
[5] Villegas, I., Rosillo, M.Á., Alarcón-de-la-Lastra, C., Vázquez-Román, V., Llorente, M., Sánchez, S., et al. (2021) Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter Pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy. Pharmaceutics, 13, 153. [Google Scholar] [CrossRef] [PubMed]
[6] Marcus, E.A., Inatomi, N., Nagami, G.T., Sachs, G. and Scott, D.R. (2012) The Effects of Varying Acidity on Helicobacter Pylori Growth and the Bactericidal Efficacy of Ampicillin. Alimentary Pharmacology & Therapeutics, 36, 972-979. [Google Scholar] [CrossRef] [PubMed]
[7] 许慧梅, 马雪妮, 程龙, 等. 二联方案在幽门螺杆菌根除治疗中的应用进展[J]. 中国微生态学杂志, 2020(2): 228-232.
[8] Deshpande, N., Sharanya, V., et al. (2016) Rapid and Ultra-Rapid Metabolizers with CYP2C19*17 Polymorphism Do Not Respond to Standard Therapy with Proton Pump Inhibitors. Meta Gene, 9, 159-164. [Google Scholar] [CrossRef] [PubMed]
[9] Unge, P., Gad, A., Gnarpe, H. and Olsson, J. (1989) Does Omeprazole Improve Antimicrobial Therapy Directed towards Gastric Campylobacter Pylori in Patients with Antral Gastritis? A Pilot Study. Scandinavian Journal of Gastroenterology, 24, 49-54. [Google Scholar] [CrossRef] [PubMed]
[10] Argueta, E.A., Alsamman, M.A., Moss, S.F. and D’Agata, E.M.C. (2021) Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter Pylori in a US Population. Gastroenterology, 160, 2181-2183.e1. [Google Scholar] [CrossRef] [PubMed]
[11] 朱健伟, 徐鹏, 王佳艳, 等. 雷贝拉唑联合阿莫西林高剂量二联疗法与铋剂四联疗法根除幽门螺杆菌感染有效性和安全性的比较研究[J]. 胃肠病学, 2022, 27(1): 17-20.
[12] Shen, C., Li, C., Lv, M., Dai, X., Gao, C., Li, L., et al. (2022) The Prospective Multiple-Centre Randomized Controlled Clinical Study of High-Dose Amoxicillin-Proton Pump Inhibitor Dual Therapy for h. Pylori Infection in Sichuan Areas. Annals of Medicine, 54, 426-435. [Google Scholar] [CrossRef] [PubMed]
[13] 霍鲁月, 吴胜男, 庄帅帅, 等. 高剂量二联疗法首次根除幽门螺杆菌疗效和安全性Meta分析[J]. 医学研究杂志, 2024, 53(2): 74-80.
[14] Song, Z., Zhou, L., Xue, Y., Suo, B., Tian, X. and Niu, Z. (2020) A Comparative Study of 14-Day Dual Therapy (Esomeprazole and Amoxicillin Four Times Daily) and Triple Plus Bismuth Therapy for First-Line helicobacter Pylori Infection Eradication: A Randomized Trial. Helicobacter, 25, e12762. [Google Scholar] [CrossRef] [PubMed]
[15] Yang, J., Zhang, Y., Fan, L., Zhu, Y., Wang, T., Wang, X., et al. (2019) Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter Pylori. American Journal of Gastroenterology, 114, 437-445. [Google Scholar] [CrossRef] [PubMed]
[16] Angelo, Z., Lorenzo, R., et al. (2015) High-Dose Esomeprazole and Amoxicillin Dual Therapy for First-Line Helicobacter Pylori Eradication: A Proof of Concept Study. Annals of Gastroenterology, 28, 448-451.
[17] Sapmaz, F., Kalkan, I.H., Atasoy, P., Basyigit, S. and Guliter, S. (2017) A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter Pylori. American Journal of Therapeutics, 24, e393-e398. [Google Scholar] [CrossRef] [PubMed]
[18] Hwong-Ruey Leow, A., Chang, J. and Goh, K. (2020) Searching for an Optimal Therapy for h Pylori Eradication: High-Dose Proton-Pump Inhibitor Dual Therapy with Amoxicillin vs. Standard Triple Therapy for 14 Days. Helicobacter, 25, e12723. [Google Scholar] [CrossRef] [PubMed]
[19] Miftahussurur, M., Pratama Putra, B. and Yamaoka, Y. (2020) The Potential Benefits of Vonoprazan as Helicobacter Pylori Infection Therapy. Pharmaceuticals, 13, Article 276. [Google Scholar] [CrossRef] [PubMed]
[20] Inatomi, N., Matsukawa, J., Sakurai, Y. and Otake, K. (2016) Potassium-Competitive Acid Blockers: Advanced Therapeutic Option for Acid-Related Diseases. Pharmacology & Therapeutics, 168, 12-22. [Google Scholar] [CrossRef] [PubMed]
[21] Echizen, H. (2015) The First-In-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics, 55, 409-418. [Google Scholar] [CrossRef] [PubMed]
[22] Graham, D.Y. (2017) Illusions Regarding Helicobacter Pyloriclinical Trials and Treatment Guidelines. Gut, 66, 2043-2046. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, C., Wang, Y., Shi, J., Zhang, C., Nie, J., Li, S., et al. (2021) The Status and Progress of First-Line Treatment against helicobacter Pylori Infection: A Review. Therapeutic Advances in Gastroenterology, 14, Article 1756284821989177. [Google Scholar] [CrossRef] [PubMed]
[24] Bunchorntavakul, C. and Buranathawornsom, A. (2021) Randomized Clinical Trial: 7-Day Vonoprazan-Based versus 14-Day Omeprazole-Based Triple Therapy for helicobacter Pylori. Journal of Gastroenterology and Hepatology, 36, 3308-3313. [Google Scholar] [CrossRef] [PubMed]
[25] 刘国华, 周娴, 叶彬明, 等. 伏诺拉生联合高剂量阿莫西林二联方案根除幽门螺杆菌的疗效[J]. 新医学, 2024, 55(3): 204-207.
[26] Takahisa, F., Mihoko, Y., Takuma, K., et al. (2019) Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter Pylori. Digestion, 2019, 1-9.
[27] Tokunaga, K., Tanaka, A., Saito, D., Miura, M., Hayashida, M., Takahashi, S., et al. (2016) Eradication Rate of New Potassium-Competitive Acid Blocker Based Regimen Compared with Rabeprazole-Based Regimen in Helicobacter Pylori Third-Line Rescue Therapy. American Journal of Gastroenterology, 111, S488. [Google Scholar] [CrossRef] 
[28] Abdel-Aziz, Y., Metz, D.C. and Howden, C.W. (2021) Review Article: Potassium-Competitive Acid Blockers for the Treatment of Acid-Related Disorders. Alimentary Pharmacology & Therapeutics, 53, 794-809. [Google Scholar] [CrossRef] [PubMed]